Clinical trial · Interventional
Prevalence of Human Papillomavirus in Barrett Esophagus Compared With Controls
NCT02549053CI-TRIAL-00019118BarrettcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study was to determine whether the prevalence of Human PapillomaVirus (HPV) was increased in patients with Barrett esophagus compared with controls in a prospective study. Secondary objective was to identify, if present, the type of Human PapillomaVirus (HPV) associated in Barrett esophagus.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Barrett Esophagus | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| esophagus biopsies (healthy zones) | Procedure | — | UNRESOLVED |
| esophagus biopsies (pathologic and healthy zones) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Barrett esophagus patients
- description
- esophagus biopsies (pathologic and healthy zones)
- interventionNames
- Procedure: esophagus biopsies (pathologic and healthy zones)
- type
- SHAM_COMPARATOR
- label
- control patients
- description
- esophagus biopsies (healthy zones)
- interventionNames
- Procedure: esophagus biopsies (healthy zones)
Primary outcomes (1)
- measure
- Research of HPV DNA in esophagus biopsies using real time polymerase chain reaction (PCR)
- timeFrame
- up to 14 months, time to develop analysis technique at the virology lab, then to collect enough biopsies to start analysis phase
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * written consent obtained before gastroscopy, * patients aged more than 18 years, * normal coagulation parameters Inclusion criteria for group A "control" and B "BE" were as follows, respectively: patients undergoing gastroscopy for non esophageal reason and presented no clinical, endoscopic or histopathological evidence of GERD or complication and patients undergoing gastroscopy for BE surveillance or suspected BE during gastroscopy. Exclusion Criteria: * written consent not obtained before gastroscopy, * inability to give informed consent, * pregnant or nursing women, * major person protected by french law, * person who is not affiliated to a social security regime, * patient who is in a exclusion period for another clinical study, * curative anticoagulation treatment, * hemostatic disturbances.
References
Publications (1)
- DERIVEDBrochard C, Ducancelle A, Pivert A, Bodin M, Ricard A, Coron E, Couffon C, Dib N, Luet D, Musquer N, Rhun ML, Bertrais S, Michalak S, Lunel-Fabiani F, Cesbron-Metivier E, Caroli-Bosc FX. Human papillomavirus does not play a role in the Barrett esophagus: a French cohort. Dis Esophagus. 2017 Nov 1;30(11):1-7. doi: 10.1093/dote/dox088. PMID 28881904